List view / Grid view
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Scientists discovered that adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.
19 July 2016 | By Niamh Louise Marriott
Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma...
In this issue: Biosimilars, Regulation, Packaging, Microfluidics, Microbiology, PAT, Antibiotic Resistance, and much more...
30 June 2016 | By Victoria White, Digital Content Producer
INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
30 June 2016 | By Victoria White, Digital Content Producer
ImmBio has reported positive results from the First-in-Human study of its novel vaccine, PnuBioVax, against the bacterial pathogen Streptococcus pneumoniae...
With the rise in drug-resistant bacterial infections heralding a new, dark era of medicine, antibiotics alternatives could one day become the first-line defence against infectious diseases. With the urgent need to find new approaches clear, Caroline Richards, Editor of European Pharmaceutical Review, interviewed Dr. Bjorn Herpers, Chief Medical Advisor of…
28 June 2016 | By Victoria White, Digital Content Producer
The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies...
28 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Zavicefta for the treatment of patients with serious Gram-negative bacterial infections...
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
21 June 2016 | By Victoria White, Digital Content Producer
The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria...
15 June 2016 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, is holding a series of formulation development and drug delivery seminars this June and July...
15 June 2016 | By Victoria White, Digital Content Producer
A study has found that women with ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy...
15 June 2016 | By Victoria White, Digital Content Producer
The proceeds will fund Phase II development of AAI202 - a novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections...
2 June 2016 | By Victoria White, Digital Content Producer
BioNTech has announced the publication of a study that describes the first example of a clinically relevant and systemic mRNA cancer immunotherapy...
23 May 2016 | By Victoria White, Digital Content Producer
Helperby is about to begin clinical studies of a completely new approach to fighting resistant bacteria following a positive meeting with the FDA...
